LPCAT2 Antibody
Description
Introduction to LPCAT2 Antibody
The LPCAT2 Antibody (lysophosphatidylcholine acyltransferase 2 antibody) is a polyclonal rabbit-derived immunoglobulin designed to detect the LPCAT2 protein in human, mouse, and rat tissues. LPCAT2 is an enzyme involved in phospholipid metabolism, specifically catalyzing the transfer of acyl groups to lysophosphatidylcholine (LPC), a precursor for phosphatidylcholine synthesis . Its functions span immune regulation, cancer progression, and lipid droplet formation . The antibody is widely used in research to study these roles through techniques like immunohistochemistry (IHC), Western blot (WB), and immunofluorescence (ICC/IF) .
Biological Functions of LPCAT2
LPCAT2 has been implicated in two primary biological contexts:
2.1. Immune Regulation and Sepsis
-
Role in Inflammation: LPCAT2 is critical for macrophage cytokine production in response to TLR4 and TLR2 ligands, such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA) . It translocates to lipid raft domains and interacts with TLR4 to regulate inflammatory gene expression .
-
Therapeutic Implications: Targeting LPCAT2 has been proposed as a strategy to modulate sepsis-related inflammation .
2.2. Cancer Progression and Lipid Metabolism
-
Colorectal Cancer (CRC): LPCAT2 inhibits CRC proliferation by inducing ferroptosis via the PRMT1/SLC7A11 axis . Overexpression of LPCAT2 reduces tumor growth in xenograft models, while knockdown exacerbates malignancy .
-
Chemotherapy Resistance: LPCAT2 promotes lipid droplet (LD) accumulation, which correlates with resistance to 5-fluorouracil and oxaliplatin in CRC .
Research Applications of the LPCAT2 Antibody
The antibody is a cornerstone in studies exploring LPCAT2’s roles in disease. Key applications include:
3.1. Immunohistochemistry (IHC)
-
CRC Tissue Analysis: Used to identify LPCAT2+ tumor subpopulations with reduced malignancy in scRNA-seq studies .
-
Liver Metastasis: Demonstrated heterogeneity in LPCAT2 expression among metastatic CRC samples, correlating with chemotherapy resistance .
3.2. Western Blot (WB)
-
Protein Validation: Confirmed LPCAT2 overexpression in engineered CRC cell lines (HCT116, DLD1) and knockdown effects in SW480, HT29 .
3.3. Immunofluorescence (ICC/IF)
-
Subcellular Localization: Revealed LPCAT2’s localization in lipid droplets (LDs) of CRC cells, with LD density correlating with LPCAT2 expression .
Key Research Findings Using the Antibody
Product Specs
Target Background
- Polymorphisms in three of these five genes (CXCL14, ITGAX, and LPCAT2) have been associated with aggressive disease development in a human genome-wide association study (GWAS) cohort consisting of 1,172 prostate cancer patients. PMID: 25411967
- Data indicate a strong negative correlation between ALOX15, FADS2, and IL5RA expression and 2-arachidonoylglycerophosphocholine levels in dual asthmatic responses. PMID: 23844124
- LPCAT1 and -2, in addition to their known functions in specialized cells, play a ubiquitous role in lipid droplet-associated lipid metabolism. PMID: 21498505
- Our enzymatic assays strongly suggest that the cDNA previously identified as LPCAT2/lyso platelet-activating factor-acetyltransferase cDNA possesses AGPAT activity. Therefore, we prefer to identify this clone as AGPAT11 as well. PMID: 20363836
- The enzyme acetyl-CoA:LYSO-PAF acetyltransferase catalyzes not only the biosynthesis of PAF upon acute inflammatory stimulation but also the incorporation of arachidonoyl-CoA to produce PAF precursor membrane glycerophospholipids for membrane biogenesis. PMID: 17182612
